NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. , a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical ...
Sol-Gel (SLGL) intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potential In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results